Comparative Pharmacology
Head-to-head clinical analysis: AMITID versus ENDEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITID versus ENDEP.
AMITID vs ENDEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Terminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant